Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells $607,316.57 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 3,401 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $178.57, for a total transaction of $607,316.57. Following the transaction, the insider directly owned 16,225 shares in the company, valued at $2,897,298.25. This trade represents a 17.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ingrid Delaet also recently made the following trade(s):

• On Wednesday, July 8th, Ingrid Delaet sold 2,737 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $178.54, for a total transaction of $488,663.98.
• On Thursday, July 9th, Ingrid Delaet sold 8,433 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $178.72, for a total transaction of $1,507,145.76.
• On Friday, May 29th, Ingrid Delaet sold 2,261 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $156.71, for a total transaction of $354,321.31.

Neurocrine Biosciences Stock Down 1.9%

Shares of NASDAQ NBIX traded down $3.44 during midday trading on Friday, reaching $177.11. 1,047,437 shares of the company’s stock traded hands, compared to its average volume of 1,103,489. The company has a market cap of $17.81 billion, a price-to-earnings ratio of 27.29, a P/E/G ratio of 0.71 and a beta of 0.39. The stock’s 50 day simple moving average is $160.84 and its 200-day simple moving average is $142.91. Neurocrine Biosciences, Inc. has a one year low of $122.14 and a one year high of $181.18.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: NBIX continues to draw bullish attention for its growth profile, with one article highlighting three reasons growth investors shouldn’t overlook Neurocrine and another pointing to strong sales and pipeline progress as reasons the stock has been trending higher. Article Title Article Title
• Positive Sentiment: Recent coverage on Phase 2 CAH study activity in young children suggests Neurocrine’s pipeline is advancing, and one note said the stock could be undervalued after the new study. Article Title Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with recent upgrades and higher price targets reinforcing confidence in NBIX’s earnings outlook and growth prospects. Article Title
• Neutral Sentiment: Neurocrine announced it will host its second-quarter 2026 earnings conference call and webcast on July 30, which is an upcoming catalyst but not a fundamental change by itself. Article Title
• Neutral Sentiment: A report that NBIX looks fair on earnings but expensive relative to other biotech names is mainly a valuation check and may limit enthusiasm, but it is not a direct negative catalyst. Article Title
• Negative Sentiment: Insider Ingrid Delaet sold shares in multiple transactions over July 7-9. The sales were made under a pre-arranged 10b5-1 plan, which makes the signal less concerning, but insider selling can still weigh on sentiment. Article Title

Institutional Investors Weigh In On Neurocrine Biosciences

Institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC raised its stake in Neurocrine Biosciences by 0.5% during the 1st quarter. NewEdge Advisors LLC now owns 13,066 shares of the company’s stock valued at $1,721,000 after acquiring an additional 68 shares during the last quarter. Huntington National Bank grew its stake in shares of Neurocrine Biosciences by 12.6% in the 4th quarter. Huntington National Bank now owns 678 shares of the company’s stock valued at $96,000 after purchasing an additional 76 shares during the last quarter. Perigon Wealth Management LLC increased its holdings in shares of Neurocrine Biosciences by 3.1% in the fourth quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock valued at $367,000 after purchasing an additional 78 shares during the period. Motley Fool Asset Management LLC increased its holdings in shares of Neurocrine Biosciences by 4.8% in the fourth quarter. Motley Fool Asset Management LLC now owns 1,693 shares of the company’s stock valued at $240,000 after purchasing an additional 78 shares during the period. Finally, Main Management ETF Advisors LLC raised its stake in shares of Neurocrine Biosciences by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 7,830 shares of the company’s stock worth $1,111,000 after purchasing an additional 80 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NBIX has been the topic of a number of analyst reports. Wedbush lifted their price target on Neurocrine Biosciences from $166.00 to $176.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Leerink Partners upped their price objective on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. Wall Street Zen raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 25th. Zacks Research upgraded Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. Finally, Truist Financial lifted their target price on Neurocrine Biosciences from $140.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $188.10.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.